Indivior stock holds near $36 after a buyback run
Published on 08/25/2026 at 12:58 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Indivior stock held near $36.11 on August 24, 2026, with a market cap of $4.35 billion and a forward EPS estimate of $4.41. The shares finished the session below the $36.87 previous close, after trading in a $35.42 to $36.81 range.
Buybacks and margins
That setup still reflects a company with unusually high profitability for a specialty-pharma name: gross margin stood at 85.73%, EBIT margin at 42.60%, and net income margin at 26.75%. Revenue growth was 13.47% year over year, while diluted EPS growth reached 227.70%, a mix that helps explain why the stock has kept a premium multiple.
Indivior's capital structure also looks cleaner than many drug peers, with $509.00 million of total debt and $222.00 million in cash. The market is still pricing the stock at 8.36 times forward earnings and 3.48 times sales, which leaves the turnaround story tied to execution rather than expansion alone.
What the numbers say
The latest figures in the market snapshot show a 52-week range of $22.22 to $42.81, and the shares remain above the 200-day moving average of $35.41. Over the past 12 months, the stock has gained 53.31%, while the S&P 500 is up 20.47% over the same stretch.
Insider activity added another point of context in June and July 2026, including a June 23, 2026 sale by the chief executive and July 13, 2026 sales by the chief scientific officer. That does not change the operating picture, but it does keep attention on how management views the share price after the strong run.
Key products
Indivior's core products remain SUBLOCADE, its monthly buprenorphine injection, and SUBOXONE Film, the buprenorphine and naloxone film used in opioid use disorder treatment. The company also lists INDV-2000, a Phase 2 candidate, alongside longer-dated pipeline work that could broaden the franchise if development stays on track.
Trading setup
For now, the key level is the 52-week high at $42.81, with the stock still trading closer to the top half of its one-year range than the low end. Indivior Pharmaceuticals, Inc. trades on Nasdaq in USD, and the next earnings date line can be carried only if a future date is confirmed by the source set or supplied as valid input.
Fact box
Company: Indivior Pharmaceuticals, Inc.
ISIN: GB00BYZ0C031
Ticker: INDV
Exchange: Nasdaq
Sector / Industry: Health Care / Pharmaceuticals
Market cap: $4.35 billion
Price (as of August 24, 2026, 3:58 p.m. ET): $36.11 USD
Previous close: $36.87
52-week range: $22.22 to $42.81
Average volume (3 months): 2.02 million
Cash: $222.00 million
Total debt: $509.00 million
Forward EPS: $4.41
Forward P/E: 8.36
Gross margin: 85.73%
EBIT margin: 42.60%
Net income margin: 26.75%
Index membership: Nasdaq
Products
SUBLOCADE and SUBOXONE Film anchor the company's opioid use disorder portfolio.
